复发性肝细胞癌:再次肝切除与经皮射频消融的随机对照长期结果
这项开放标签随机临床试验纳入240例早期复发性肝细胞癌患者,1:1接受再次肝切除或经皮射频消融,中位随访44.3个月。
要点
- 肿瘤直径>3 cm或AFP>200 ng/mL者,射频消融的总生存可能更差。
核心结论
- 再次肝切除可能与更好的局部控制相关,尤其对于肿瘤直径>3 cm或AFP>200 ng/mL的患者可能带来更长的生存获益。
研究设计与样本
- 开放标签随机临床试验,在中国东方肝胆外科医院和国家肝癌中心开展。
- 2010年6月3日至2013年1月15日共随机240例复发性肝细胞癌患者(单发结节直径≤5 cm;结节≤3个且每个≤3 cm;无宏观血管侵犯或远处转移),1:1分配至再次肝切除组(n=120)或经皮射频消融组(n=120)。
- 中位随访44.3个月(范围4.3-90.6个月),末次随访2018年1月15日。
主要发现
- 亚组分析中,肿瘤直径>3 cm者射频消融的总生存更差(HR 1.72,95%CI 1.05-2.84);AFP>200 ng/mL者射频消融的总生存也更差(HR 1.85,95%CI 1.15-2.96)。
临床怎么用
- 对于早期复发性肝细胞癌,再次肝切除和射频消融均可作为治疗选择,需结合肿瘤大小、AFP水平及患者手术耐受性个体化决策。
- 肿瘤直径>3 cm或AFP>200 ng/mL的患者,再次肝切除可能带来更好的局部控制和长期生存,应优先考虑手术。
- 射频消融并发症少但局部再复发风险较高,选择时需权衡局部控制与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Repeat hepatectomy and percutaneous radiofrequency ablation (PRFA) are most commonly used to treat early-stage recurrent hepatocellular carcinoma (RHCC) after initial resection, but previous studies comparing the effectiveness of the 2 treatments have reported conflicting results. OBJECTIVE: To compare the long-term survival outcomes after repeat hepatectomy with those after PRFA among patients with early-stage RHCC. DESIGN, SETTING, AND PARTICIPANTS: This open-label randomized clinical trial was conducted at the Eastern Hepatobiliary Surgery Hospital and the National Center for Liver Cancer of China. A total of 240 patients with RHCC (with a solitary nodule diameter of ≤5 cm; 3 or fewer nodules, each ≤3 cm in diameter; and no macroscopic vascular invasion or distant metastasis) were randomized 1:1 to receive repeat hepatectomy or PRFA between June 3, 2010, and January 15, 2013. The median (range) follow-up time was 44.3 (4.3-90.6) months (last follow-up, January 15, 2018). Data analysis was conducted from June 15, 2018, to September 28, 2018. INTERVENTIONS: Repeat hepatectomy (n = 120) or PRFA (n = 120). MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (OS). Secondary outcomes included repeat recurrence-free survival (rRFS), patterns of repeat recurrence, and therapeutic safety. RESULTS: Among the 240 randomized patients (216 men [90.0%]; median [range] age, 53.0 [24.0-59.0] years), 217 completed the trial. In the intention-to-treat (ITT) population, the 1-year, 3-year, and 5-year OS rates were 92.5% (95% CI, 87.9%-97.3%), 65.8% (95% CI, 57.8%-74.8%), and 43.6% (95% CI, 35.5%-53.5%), respectively, for the repeat hepatectomy group and 87.5% (95% CI, 81.8%-93.6%), 52.5% (95% CI, 44.2%-62.2%), and 38.5% (95% CI, 30.6%-48.4%), respectively, for the PRFA group (P = .17). The corresponding 1-year, 3-year, and 5-year rRFS rates were 85.0% (95% CI, 78.8%-91.6%), 52.4% (95% CI, 44.2%-62.2%), and 36.2% (95% CI, 28.5%-46.0%), respectively, for the repeat hepatectomy group and 74.2% (95% CI, 66.7%-82.4%), 41.7% (95% CI, 33.7%-51.5%), and 30.2% (95% CI, 22.9%-39.8%), respectively, for the PRFA group (P = .09). Percutaneous radiofrequency ablation was associated with a higher incidence of local repeat recurrence (37.8% vs 21.7%, P = .04) and early repeat recurrence than repeat hepatectomy (40.3% vs 23.3%, P = .04). In subgroup analyses, PRFA was associated with worse OS vs repeat hepatectomy among patients with an RHCC nodule diameter greater than 3 cm (hazard ratio, 1.72; 95% CI, 1.05-2.84) or an α fetoprotein level greater than 200 ng/mL (hazard ratio, 1.85; 95% CI, 1.15-2.96). Surgery had a higher complication rate than did ablation (22.4% vs 7.3%, P = .001). CONCLUSIONS AND RELEVANCE: No statistically significant difference was observed in survival outcomes after repeat hepatectomy vs PRFA for patients with early-stage RHCC. Repeat hepatectomy may be associated with better local disease control and long-term survival in patients with an RHCC diameter greater than 3 cm or an AFP level greater than 200 ng/mL. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00822562.
引用
- Xia Y, Li J, Liu G, et al. Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 31774468. doi:10.1001/jamaoncol.2019.4477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。